MRTX Mirati Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: MRTX

Price (delayed)

$39.1

Market cap

$2.27B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$13.18

Enterprise value

$2.08B

Mirati Therapeutics is a late-stage biotechnology company whose mission is to discover, design and deliver breakthrough therapies to transform the lives of patients with cancer and their loved ones. The ...

Highlights
Mirati Therapeutics's debt has decreased by 4.8% YoY
MRTX's revenue has dropped by 83% year-on-year but it is up by 5% since the previous quarter
Mirati Therapeutics's gross profit has plunged by 84% YoY
The quick ratio is down by 34% year-on-year and by 28% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://mirati.com
Peers: TA

Key stats

What are the main financial stats of MRTX
Market
Shares outstanding
58.04M
Market cap
$2.27B
Enterprise value
$2.08B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.26
Price to sales (P/S)
176.8
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
167.07
Earnings
Revenue
$12.44M
EBIT
-$740.36M
EBITDA
-$737.43M
Free cash flow
-$575.42M
Per share
EPS
-$13.18
Free cash flow per share
-$10.23
Book value per share
$17.3
Revenue per share
$0.22
TBVPS
$21.12
Balance sheet
Total assets
$1.2B
Total liabilities
$206.13M
Debt
$43.66M
Equity
$996.52M
Working capital
$949.51M
Liquidity
Debt to equity
0.04
Current ratio
6.96
Quick ratio
6.8
Net debt/EBITDA
0.26
Margins
EBITDA margin
-5,929.8%
Gross margin
95.2%
Net margin
-5,957.4%
Operating margin
-6,108%
Efficiency
Return on assets
-56.9%
Return on equity
-66%
Return on invested capital
-79.2%
Return on capital employed
-71%
Return on sales
-5,953.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MRTX stock price

How has the Mirati Therapeutics stock price performed over time
Intraday
0.85%
1 week
-5.56%
1 month
-13.28%
1 year
-52.42%
YTD
-13.71%
QTD
-13.71%

Financial performance

How have Mirati Therapeutics's revenue and profit performed over time
Revenue
$12.44M
Gross profit
$11.84M
Operating income
-$759.59M
Net income
-$740.87M
Gross margin
95.2%
Net margin
-5,957.4%
Mirati Therapeutics's gross profit has plunged by 84% YoY
MRTX's revenue has dropped by 83% year-on-year but it is up by 5% since the previous quarter
The company's operating income fell by 33% YoY
Mirati Therapeutics's net income has decreased by 27% YoY

Growth

What is Mirati Therapeutics's growth rate over time

Valuation

What is Mirati Therapeutics stock price valuation
P/E
N/A
P/B
2.26
P/S
176.8
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
167.07
The EPS fell by 18% YoY
MRTX's price to book (P/B) is 68% lower than its 5-year quarterly average of 7.0 and 32% lower than its last 4 quarters average of 3.3
MRTX's equity is down by 29% YoY and by 12% from the previous quarter
MRTX's revenue has dropped by 83% year-on-year but it is up by 5% since the previous quarter
The price to sales (P/S) is 69% lower than the 5-year quarterly average of 571.1 but 9% higher than the last 4 quarters average of 162.0

Efficiency

How efficient is Mirati Therapeutics business performance
The company's return on equity fell by 38% YoY and by 9% QoQ
Mirati Therapeutics's return on assets has decreased by 36% YoY and by 8% QoQ
MRTX's return on invested capital is down by 36% year-on-year and by 7% since the previous quarter
The ROS rose by 4.8% QoQ

Dividends

What is MRTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MRTX.

Financial health

How did Mirati Therapeutics financials performed over time
MRTX's current ratio is down by 34% year-on-year and by 28% since the previous quarter
The quick ratio is down by 34% year-on-year and by 28% since the previous quarter
Mirati Therapeutics's debt is 96% less than its equity
The debt to equity has grown by 33% YoY
MRTX's equity is down by 29% YoY and by 12% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.